Global Anticoagulant Market, By Drug Class (Factor Xa Inhibitors, Heparin and LMWH, Vitamin K Antagonist, Others), Indication (Atrial Fibrillation and Heart Attack, Stroke, Deep vein thrombosis (DVT), Pulmonary Embolism (PE), Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
When blood thickens and becomes a semi-solid mass in any part of the body, clots occur. Stroke, heart attack, pulmonary embolism, transient ischemic episodes, and deep vein thrombosis are all major consequences of this (DVT). As a result, anticoagulant medications are being prescribed by doctors all over the world to those who are at risk of clotting. These medications aid in blood thinning, blood clotting prevention or reduction, and clotting time prolongation. Warfarin, apixaban, dabigatran, and rivaroxaban are commonly available in capsule or tablet form.
Data Bridge Market Research analyses that the anticoagulant market was valued at USD 34.0 billion in 2021 and is expected to reach USD 65.11 billion by 2029, registering a CAGR of 8.46% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Drug Class (Factor Xa Inhibitors, Heparin and LMWH, Vitamin K Antagonist, Others), Indication (Atrial Fibrillation and Heart Attack, Stroke, Deep vein thrombosis (DVT), Pulmonary Embolism (PE), Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Hikma Pharmaceuticals PLC (U.K.), Fresenius Kabi AG (Germany), Eisai Co., Ltd. (Japan), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), DAIICHI SANKYO COMPANY, LIMITED (Japan), Boehringer Ingelheim International GmbH. (Germany), Dr. Reddy’s Laboratories Ltd. (India), Aspen Holdings (South Africa)
Blood thinners are anticoagulants, which are chemical agents that inhibit blood coagulation and blood clotting time. Anticoagulants are a pharmacological class of drugs used to treat thrombotic diseases. Oral anticoagulants come in pill, tablet, and injectable dose forms. Herapins, low molecular weight heparins (LMWHs), warfarin, direct thrombin inhibitors and factor Xa inhibitors are the most common anticoagulants (DTIs). Heparin is an injectable anticoagulant that is commonly used in hospitals to prevent blood clotting. Subcutaneous injections of LMWHs are given twice a day to treat DVT.
Anticoagulant Market Dynamics
- Increasing cases of coronavirus infection globally
The rising cases of coronavirus infection globally is anticipated to drive the anticoagulant market's growth. According to new research, hypercoagulability in those infected by the coronavirus disease (COVID-19) pandemic could be one of the major causes of death globally. As a result, the rising number of instances is driving up demand for anticoagulant medications to treat thrombosis in critically unwell or hospitalized patients.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of anticoagulant market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Increasing prevalence of chronic diseases
The increased prevalence of chronic illness in both the elderly and middle-aged populations will fuel industry growth. Coronary heart disease and myocardial infarction (MI) are regarded a major public health concern around the world. In the United States, the number of patients suffering from coronary artery disease has increased noticeably. According to the American Heart Association (AHA), roughly one in every seven deaths in the United States occurred in 2018. Adults with cardiac infection account for almost 7.9 million (3 percent) people, according to the survey. As a result, demand for anticoagulant treatment, including surgical procedures, has increased dramatically.
Furthermore, surging geriatric population and rise in the number of infected patients globally will result in the expansion of anticoagulant market. Along with this, sedentary lifestyle of people such as rising addiction of smoking as well as extended sitting and favourable reimbursement policies will enhance the growth rate of the market.
- Technological advancement
The industry is projected to benefit from technological advancements in the development of anticoagulant products. Advanced technologies such as microfluidics, fluorescent microscopy, electrochemical sensing, photoacoustic detection, and micro/nano electromechanical systems (MEMS/NEMS) have been used to develop highly accurate, robust, and cost-effective anticoagulant products, according to a study published in the Frontier in Biotehnology and Bioengineering in December 2019.
Moreover, the market's growth is fueled by an increase in the number of research and development activities and emerging new markets. These factors will provide beneficial opportunities for the anticoagulant market growth.
- Side effects linked with anticoagulants
Anticoagulant side effects may stymie market growth over the projection period. Heparin-induced thrombocytopenia causes the immune system to produce antibodies against the body's own platelets, which increases the risk of bleeding. For illustration, the FDA gets roughly 450,000 adverse medication events per year, with 3.8 percent of those involving heparin, reducing market income. Warfarin can also cause chrondrodysplasia punctata, asplenia, and foetal malformations, among other things. The industry's value will be harmed by such side consequences. Despite the fact that important market leaders are attempting to develop novel products, side effects may reduce their acceptance rate.
On the other hand, high cost associated with the drug development and distribution will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the anticoagulant market. Additionally, lack of awareness among people and strict government regulations will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This anticoagulant market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anticoagulant market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Anticoagulant market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Anticoagulant Market
Due to the rapid speed of research, COVID-19 infection is predicted to have a significant influence on the anticoagulant market. As per a study published in the American Journal of Cardiovascular Drugs in 2020, more than ten clinical trials are currently underway to assess the potential of anticoagulants in COVID-19 patients, and research on parenteral administration strategies for these drugs is being conducted for use in critically ill COVID-19 patients. Furthermore, patients with COVID-19, both confirmed and suspected, should have access to follow-up care with low-dose anticoagulants, according to a World Health Organization Update published in January 2021. As a result, anticoagulant demand surged during COVID-19.
- In December 2020, Natco Pharma had announced the launch of an anticoagulant medication named Rivaroxaban (RPIGAT). Rivaroxaban is an anticoagulant drug that treats and prevents blood clots. In India, Bayer markets the drug as Xarelto.
Global Anticoagulant Market Scope
The anticoagulant market is segmented on the basis of drug class, indication, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Atrial Fibrillation and Heart Attack
- Deep vein thrombosis (DVT)
- Pulmonary Embolism (PE)
- Factor Xa Inhibitors
- Heparin and LMWH
- Vitamin K Antagonist
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Anticoagulant Market Regional Analysis/Insights
The anticoagulant market is analysed and market size insights and trends are provided by country, drug class, indication, route of administration, end-users and distribution channel as referenced above.
The countries covered in the anticoagulant market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the anticoagulant market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing demand of diseases specific treatment and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, growing presence of major key players and rise in adoption of newer technologies will further propel the market’s growth rate in this region.
Asia-Pacific is expected to be the fastest growing region during the forecast period of 2022-2029 due to surging number of geriatric population in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Anticoagulant Market Share Analysis
The anticoagulant market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to anticoagulant market.
Some of the major players operating in the anticoagulant market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Fresenius Kabi AG (Germany)
- Eisai Co., Ltd. (Japan)
- Bristol-Myers Squibb Company (U.S.)
- Bayer AG (Germany)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Boehringer Ingelheim International GmbH. (Germany)
- Dr. Reddy’s Laboratories Ltd. (India)
- Aspen Holdings (South Africa)
Research Methodology: Global Anticoagulant Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.